Eli Lilly Is Near Its High. Bank of America Sees Another 19%
Bank of America raised its price target for Eli Lilly to $1,600, citing strong revenue growth and potential in new drugs. Lilly's Q3 revenue grew 39%, and it raised its 2026 guidance to $91B-$92B. The stock is up 25% in 2026 but remains 7% below its recent high. Bank of America's target is based on Lilly's growth profile and upcoming drug developments.
How this was made
The 30-second read
Why it matters
The target increase could attract new buying, but valuation remains high.
Market read
Analyst upgrade for a mega‑cap biotech may influence sector sentiment and short‑term price action.
What to watch
Potential regulatory or competitive risks from Novo Nordisk are not fully priced in.
Background
Eli Lilly reported strong Q3 revenue growth and raised its 2026 revenue guidance, prompting analyst target revisions.
Ticker impact
Bank of America raised its price target for Eli Lilly to $1,600, a 19% increase, and kept a Buy rating, indicating fresh analyst optimism.
likely upward pressure as investors price in the higher target
Target raise is new information and aligns with strong revenue growth and guidance, prompting buying interest.
Market effects
Positive outlook may lift other pharma peers as growth expectations rise.
U.S. biotech sector could see modest gains.
Limited to investors tracking large-cap biotech stocks.
Counterpoint
Some may argue the target is overly optimistic given valuation levels.
Key entities
- companyEli Lilly (LLY)
Pharmaceutical company receiving an upgraded price target.
- analystBank of America
Equity research firm that raised the price target.





